DK2279737T3 - Heterocycliske forbindelser, der er aktive som beta-lactamaseinhibitorer - Google Patents

Heterocycliske forbindelser, der er aktive som beta-lactamaseinhibitorer

Info

Publication number
DK2279737T3
DK2279737T3 DK10177533.6T DK10177533T DK2279737T3 DK 2279737 T3 DK2279737 T3 DK 2279737T3 DK 10177533 T DK10177533 T DK 10177533T DK 2279737 T3 DK2279737 T3 DK 2279737T3
Authority
DK
Denmark
Prior art keywords
beta
heterocyclic compounds
lactamase inhibitors
compounds active
active
Prior art date
Application number
DK10177533.6T
Other languages
English (en)
Inventor
Jozsef Aszodi
Claude Fromentin
Maxime Lampilas
David Alun Rowlands
Original Assignee
Novexel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27619669&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2279737(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novexel filed Critical Novexel
Application granted granted Critical
Publication of DK2279737T3 publication Critical patent/DK2279737T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK10177533.6T 2002-01-28 2003-01-27 Heterocycliske forbindelser, der er aktive som beta-lactamaseinhibitorer DK2279737T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0200951A FR2835186B1 (fr) 2002-01-28 2002-01-28 Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
EP03709903A EP1480644B1 (fr) 2002-01-28 2003-01-27 Composes heterocycliques, actifs comme inhibiteurs de beta-lactamases

Publications (1)

Publication Number Publication Date
DK2279737T3 true DK2279737T3 (da) 2013-02-11

Family

ID=27619669

Family Applications (2)

Application Number Title Priority Date Filing Date
DK10177533.6T DK2279737T3 (da) 2002-01-28 2003-01-27 Heterocycliske forbindelser, der er aktive som beta-lactamaseinhibitorer
DK03709903.3T DK1480644T3 (da) 2002-01-28 2003-01-27 Heterocykliske forbindelser, der er aktive som inhibitorer af beta-lactamaser

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK03709903.3T DK1480644T3 (da) 2002-01-28 2003-01-27 Heterocykliske forbindelser, der er aktive som inhibitorer af beta-lactamaser

Country Status (44)

Country Link
US (4) US7612087B2 (da)
EP (2) EP1480644B1 (da)
JP (1) JP4472346B2 (da)
KR (1) KR100979079B1 (da)
CN (3) CN100563653C (da)
AR (2) AR038234A1 (da)
AT (1) ATE484281T1 (da)
AU (1) AU2003214335B2 (da)
BE (1) BE2016C069I2 (da)
BR (1) BRPI0307267B8 (da)
CA (1) CA2474043C (da)
CL (1) CL2011000009A1 (da)
CO (1) CO5601014A2 (da)
CR (2) CR7387A (da)
CY (3) CY1111061T1 (da)
DE (1) DE60334527D1 (da)
DK (2) DK2279737T3 (da)
EA (1) EA007220B1 (da)
EC (1) ECSP045193A (da)
ES (2) ES2401855T3 (da)
FR (2) FR2835186B1 (da)
HR (1) HRP20040686B1 (da)
HU (1) HUS1600055I1 (da)
IL (1) IL163167A (da)
JO (1) JO2646B1 (da)
LT (1) LTC1480644I2 (da)
MA (1) MA26351A1 (da)
MX (1) MXPA04006621A (da)
MY (1) MY140638A (da)
NL (1) NL300847I2 (da)
NO (3) NO335195B1 (da)
NZ (1) NZ533936A (da)
OA (1) OA12761A (da)
PE (1) PE20030969A1 (da)
PL (1) PL220725B1 (da)
PT (2) PT1480644E (da)
RS (1) RS52137B (da)
SI (2) SI2279737T1 (da)
TN (1) TNSN04137A1 (da)
TW (1) TWI293071B (da)
UA (1) UA80271C2 (da)
UY (1) UY27626A1 (da)
WO (1) WO2003063864A2 (da)
ZA (1) ZA200405607B (da)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2812635B1 (fr) * 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
FR2835186B1 (fr) * 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
FR2844273B1 (fr) 2002-09-05 2008-04-04 Aventis Pharma Sa Nouveaux composes heterocycliques, procede et intermediaires de preparation et utilisation comme medicament, notamment comme inhibiteurs de beta-lactamases et anti-bacteriens.
FR2848210B1 (fr) * 2002-12-06 2007-10-19 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens et inhibiteurs de beta-lactamases
US7439253B2 (en) 2002-12-06 2008-10-21 Novexel Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors
US8900637B2 (en) * 2005-12-02 2014-12-02 Lupin Limited Stable taste masked formulations of cephalosporins
EP2484680B1 (en) * 2005-12-07 2013-06-26 Basilea Pharmaceutica AG Useful Combinations of Monobactam Antibiotics with beta-Lac-tamase Inhibitors
JP5539717B2 (ja) * 2006-07-14 2014-07-02 塩野義製薬株式会社 オキシム化合物およびその使用
BRPI0717348A2 (pt) * 2006-10-23 2013-10-15 Irm Llc Composições e processos para inibir captecina proteases
JP5323063B2 (ja) * 2007-05-31 2013-10-23 塩野義製薬株式会社 オキシイミノ化合物およびその使用
FR2921060B1 (fr) * 2007-09-14 2012-06-15 Novexel Nouveau procede de preparation d'une piperidine disubsituee et nouveaux intermediaires
JP5038509B2 (ja) 2008-01-18 2012-10-03 メルク・シャープ・エンド・ドーム・コーポレイション β−ラクタマーゼ阻害剤
WO2009114921A1 (en) * 2008-03-17 2009-09-24 Dmitrienko Gary I INHIBITORS OF CLASS B AND CLASS D β-LACTAMASES
FR2930553B1 (fr) * 2008-04-29 2010-05-21 Novexel Composes azabicycliques, leur preparation et leur utilisation comme medicaments, notamment inhibiteurs de beta-lactamases
WO2009151152A1 (en) * 2008-06-11 2009-12-17 Shionogi & Co., Ltd. Oxycarbamoyl compounds and the use thereof
FR2936798B1 (fr) * 2008-10-03 2012-09-28 Novexel Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens.
FR2937034B1 (fr) * 2008-10-10 2012-11-23 Novexel Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens
FR2936951B1 (fr) * 2008-10-10 2010-12-03 Novexel Nouvelles combinaisons de composes heterocycliques azotes antibacteriens avec d'autres composes antibacteriens et leur utilisation comme medicaments
FR2951171A1 (fr) 2009-10-09 2011-04-15 Novexel Nouveau sel de sodium d'un compose azabicyclique sous forme enantiomere cristallisee et nouvelles formes polymorphes et pseudopolymorphes ainsi que leur preparation
AU2014244235B2 (en) * 2009-10-09 2016-04-21 Pfizer Ireland Pharmaceuticals Polymorphic and pseudopolymorphic forms of a pharmaceutical compound
RU2599791C2 (ru) 2010-08-10 2016-10-20 Ремпекс Фармасьютикэлз, Инч. Циклические бороновые кислотно-эфирные производные и их использование в терапии
US8772490B2 (en) 2010-12-22 2014-07-08 Meiji Seika Pharma Co., Ltd. Optically active diazabicyclooctane derivatives and process for preparing the same
SI2657234T1 (sl) * 2010-12-22 2017-06-30 Meiji Seika Pharma Co., Ltd. Derivat optično-aktivnega diazabiciklooktana in metoda za njegovo izdelavo
CA2780403C (en) * 2011-06-17 2020-04-21 Forest Laboratories Holdings Ltd. Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof
RU2636147C1 (ru) * 2011-08-27 2017-11-21 Вокхардт Лимитед Производные 1,6-диазабицикло[3,2,1]октан-7-она и их применение при лечении бактериальных инфекционных болезней
US20130053565A1 (en) * 2011-08-29 2013-02-28 University Of Utah Research Foundation Substituted 3-piperidone compounds
US9102683B2 (en) 2011-08-29 2015-08-11 University Of Utah Research Foundation Heterocyclic compounds
WO2013033461A1 (en) 2011-08-31 2013-03-07 Rempex Pharmaceuticals, Inc. Heterocyclic boronic acid ester derivatives and therapeutic uses thereof
US8969567B2 (en) * 2011-09-13 2015-03-03 Wockhardt Ltd. Nitrogen containing compounds and their use
US8754102B2 (en) * 2011-09-13 2014-06-17 Wockhardt Ltd. Nitrogen containing compounds and their use
US8796257B2 (en) 2011-12-02 2014-08-05 Naeja Pharmaceutical Inc. Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
US9505761B2 (en) 2011-12-02 2016-11-29 Fedora Pharmaceuticals Inc. Bicyclic compounds and their use as antibacterial agents and beta-lactamase inhibitors
WO2013149121A1 (en) 2012-03-30 2013-10-03 Cubist Pharmaceuticals, Inc. 1,3,4-oxadiazole and 1,3,4-thiadiazole beta-lactamase inhibitors
AU2013237869A1 (en) 2012-03-30 2014-10-23 Cubist Pharmaceuticals, Inc. Isoxazole beta-lactamase inhibitors
US8916709B2 (en) 2012-03-30 2014-12-23 Cubist Pharmaceuticals, Inc. 1,2,4-oxadiazole and 1,2,4-thiadiazole β-lactamase inhibitors
US8969570B2 (en) 2012-03-30 2015-03-03 Cubist Pharmaceuticals, Inc. Beta-lactamase inhibitors
AR090539A1 (es) * 2012-04-02 2014-11-19 Astrazeneca Ab COMPUESTOS INHIBIDORES DE b LACTAMASA
US9156858B2 (en) 2012-05-23 2015-10-13 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
TWI565707B (zh) 2012-05-30 2017-01-11 明治製菓藥業股份有限公司 新穎β－內醯胺酶抑制劑及其製造方法
US10561675B2 (en) 2012-06-06 2020-02-18 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
EP2961751B1 (en) * 2012-08-25 2018-03-21 Wockhardt Limited 1,6- diazabicyclo [3,2,1]octan- 7- one derivatives and their use in the treatment of bacterial infections
UA111925C2 (uk) * 2012-12-11 2016-06-24 Федора Фармасьютікалз Інк. БІЦИКЛІЧНІ СПОЛУКИ ТА ЇХ ВИКОРИСТАННЯ ЯК АНТИБАКТЕРІАЛЬНИХ АГЕНТІВ ТА ІНГІБІТОРІВ β-ЛАКТАМАЗИ
JP6324409B2 (ja) 2013-01-04 2018-05-16 レンペックス・ファーマシューティカルズ・インコーポレイテッド ボロン酸誘導体及びその治療的使用
AU2014204045B2 (en) 2013-01-04 2018-10-18 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US9241947B2 (en) 2013-01-04 2016-01-26 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US9101638B2 (en) 2013-01-04 2015-08-11 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
EP2970338A1 (en) 2013-03-14 2016-01-20 Merck Sharp & Dohme Corp. Crystalline form of a beta-lactamase inhibitor
TWI644908B (zh) 2013-09-24 2018-12-21 明治製菓藥業股份有限公司 二氮雜二環辛烷衍生物之製法及其中間體
WO2015051101A1 (en) 2013-10-02 2015-04-09 Cubist Pharmaceuticals, Inc. B-lactamase inhibitor picoline salt
KR102388529B1 (ko) 2013-10-08 2022-04-20 메이지 세이카 파루마 가부시키가이샤 디아자비시클로옥탄 유도체의 결정과 그의 제조법
KR20160115941A (ko) * 2014-02-20 2016-10-06 욱크하르트 리미티드 항세균제를 포함하는 제약학적 조합
CN103896936A (zh) * 2014-03-20 2014-07-02 西安交通大学 (5s,6r)氯唑西林青霉噻唑酸盐及其制备方法和应用
WO2015171398A1 (en) 2014-05-05 2015-11-12 Rempex Pharmaceuticals, Inc. Salts and polymorphs of cyclic boronic acid ester derivatives and therapeutic uses thereof
RS59488B1 (sr) 2014-05-05 2019-12-31 Rempex Pharmaceuticals Inc Sinteza boronatnih soli i njihove upotrebe
JP6672176B2 (ja) 2014-05-19 2020-03-25 レンペックス・ファーマシューティカルズ・インコーポレイテッド ボロン酸誘導体およびその治療的使用
CN104059083B (zh) * 2014-05-27 2017-01-04 浙江工业大学 一种手性二环己内酰胺类化合物的不对称合成方法
AU2015284307A1 (en) 2014-07-01 2017-02-02 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US9968593B2 (en) 2014-11-17 2018-05-15 Entasis Therapeutics Limited Combination therapy for treatment of resistant bacterial infections
US10662205B2 (en) 2014-11-18 2020-05-26 Qpex Biopharma, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
RU2732129C2 (ru) 2014-12-05 2020-09-11 Мейдзи Сейка Фарма Ко., Лтд. Способ производства кристаллов производного диазабициклооктана и стабильного лиофилизированного препарата
US20180051041A1 (en) 2015-03-17 2018-02-22 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
JP6767392B2 (ja) * 2015-05-07 2020-10-14 ミュタビリスＭｕｔａｂｉｌｉｓ 複素環式化合物及び細菌感染の治療又は予防におけるその使用
CN107531709B (zh) * 2015-09-16 2020-10-23 吉林四环制药有限公司 β-内酰胺酶抑制剂及其用途
EA201890847A1 (ru) 2015-10-02 2018-08-31 Легокем Байосайенсез, Инк. Композиции и способы ингибирования бета-лактамазы
WO2017156458A1 (en) 2016-03-11 2017-09-14 University Of South Florida Beta-lactamase inhibitors, formulations, and uses thereof
EP3156400B1 (en) 2016-05-27 2019-05-15 Valoralia I Más D, SL Dihydrooxadiazine compounds for treating infections and cancer
JP7060245B2 (ja) 2016-06-30 2022-04-26 キューペックス バイオファーマ， インコーポレイテッド ボロン酸誘導体およびその治療的使用
CN106279163A (zh) * 2016-08-12 2017-01-04 上海龙翔生物医药开发有限公司 一种合成阿维巴坦及其中间体光学异构体的方法
CN107789355B (zh) * 2016-09-07 2022-04-12 湘北威尔曼制药股份有限公司 含有哌拉西林的复方药物组合物及其应用
SMT202200397T1 (it) 2016-09-16 2022-11-18 Entasis Therapeutics Ltd Composti inibitori di beta-lattamasi
JOP20190061A1 (ar) * 2016-09-28 2019-03-26 Novartis Ag مثبطات بيتا-لاكتاماز
CN106699756B (zh) * 2016-12-30 2019-10-29 淄博鑫泉医药技术服务有限公司 β内酰胺酶抑制剂阿维巴坦的合成方法
MX2019009362A (es) 2017-02-06 2019-10-22 Mutabilis Compuestos heterociclicos novedosos y sus usos en la prevencion o el tratamiento de infecciones bacterianas.
PT3630111T (pt) 2017-05-08 2022-03-01 Entasis Therapeutics Inc Compostos e métodos de tratamento de infeções bacterianas
WO2018234962A1 (en) 2017-06-20 2018-12-27 Wockhardt Limited Process for o-sulfonation of 1,6-diazabicyclo[3.2.1]octane compounds
CA3078627A1 (en) 2017-10-11 2019-04-18 Qpex Biopharma, Inc. Boronic acid derivatives and synthesis thereof
CN109678856B (zh) * 2017-10-18 2020-09-25 新发药业有限公司 一种阿维巴坦中间体的制备方法
TW201925201A (zh) * 2017-11-10 2019-07-01 日商鹽野義製藥股份有限公司 二氮雜二環辛烷衍生物
EP3781576B1 (en) 2018-04-20 2024-06-12 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
DK3833665T3 (da) 2018-08-09 2023-10-09 Antabio Sas Diazabicyclooctanoner som hæmmere af serin-beta-lactamaser
US11905286B2 (en) 2018-08-09 2024-02-20 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases
CN109942579B (zh) * 2019-04-18 2021-06-22 成都千禧莱医药科技有限公司 β-内酰胺酶抑制剂含脲双环化合物及其制备方法和应用
WO2022047603A1 (en) 2020-09-01 2022-03-10 Ningxia Academy Of Agriculture And Forestry Sciences Beta-lactamase inhibitors and their preparation
WO2022047790A1 (en) * 2020-09-07 2022-03-10 Ningxia Academy Of Agriculture And Forestry Sciences Amidine substituted bicyclic compounds, their preparation, their use as antibacterial agents and beta-lactamase inhibitors
EP4146651A4 (en) 2021-05-07 2024-06-05 Ningxia Academy of Agriculture and Forestry Sciences SULFONYLAMIDINE SUBSTITUTED COMPOUNDS AND THEIR USE AS BETA-LACTAMASE INHIBITORS
WO2023060369A1 (en) * 2021-10-11 2023-04-20 Ningxia Academy Of Agriculture And Forestry Sciences Novel carbimidate substituted bicyclic compounds and their use as beta-lactamase inhibitors
KR20240041506A (ko) 2022-09-23 2024-04-01 주식회사 경보제약 아비박탐 나트륨 염의 안정한 일수화물 형태 및 그의 제조 방법
CN116375706B (zh) * 2023-02-22 2025-02-14 时森海(杭州)医药科技有限公司 阿维巴坦钠关键中间体及其制备方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0260057A3 (en) 1986-09-02 1989-02-01 The University Of Melbourne 2-oxo-4-carboxy-pyrimidines
JP2955358B2 (ja) 1989-06-09 1999-10-04 ファルマシア・アンド・アップジョン・カンパニー 中枢神経系活性を有する複素環系アミン
FR2676230B1 (fr) 1991-05-07 1993-08-27 Centre Nat Rech Scient Nouveaux derives de pyrrolo [1,4]-benzodiazepines, leur procede de preparation et medicaments les contenant.
JPH05339263A (ja) 1992-06-08 1993-12-21 Wakunaga Pharmaceut Co Ltd ジヒドロピリジン誘導体
DK1227103T3 (da) 1993-09-29 2006-11-27 Univ Maryland Nukleosider og nukleotider med forstörrede ringe
WO1995018129A1 (en) * 1993-12-29 1995-07-06 Pfizer Inc. Diazabicyclic neurokinin antagonists
EP0702004A2 (de) 1994-09-15 1996-03-20 Ciba-Geigy Ag 2,9-Diamino- und 2-amino-8-carbamoyl-4-hydroxy-alkansäureamid-derivative
GB9505538D0 (en) 1995-03-18 1995-05-03 Ciba Geigy Ag New compounds
SE9504618D0 (sv) 1995-12-22 1995-12-22 Astra Ab New Compounds
HUP9900973A3 (en) * 1996-01-03 2000-04-28 Smithkline Beecham Plc Carbamoyloxy derivatives of mutiline with antibacterial activity, pharmaceutical compns. contg. them and process for preparing the said compds.
UA51716C2 (uk) 1996-07-08 2002-12-16 Авентіс Фармасьютікалз Продактс Інк. Сполуки, що мають гіпотензивну, кардіопротекторну, анти-ішемічну та антиліполітичну властивості, фармацевтична композиція та способи лікування
DE19627431A1 (de) * 1996-07-08 1998-01-15 Bayer Ag Heterocyclisch kondensierte Pyridine
HUP0001741A3 (en) * 1996-08-02 2000-11-28 Smithkline Beecham Plc Azabicyclic carbamoyloxy mutilin derivatives for antibacterial use, process for preparing them, pharmaceuticals contg. them and their use
TW527355B (en) 1997-07-02 2003-04-11 Bristol Myers Squibb Co Inhibitors of farnesyl protein transferase
US5994340A (en) * 1997-08-29 1999-11-30 Synphar Laboratories, Inc. Azetidinone derivatives as β-lactamase inhibitors
US6197339B1 (en) 1997-09-30 2001-03-06 Pharmacia & Upjohn Company Sustained release tablet formulation to treat Parkinson's disease
UY25225A1 (es) * 1997-10-29 2000-12-29 Smithkline Beecham Plc Derivados de pleuromutilina utiles como agentes antimicrobianos
US6329389B1 (en) 1998-04-08 2001-12-11 Takeda Chemical Industries, Ltd. Amine compounds, their production and use
WO2000000479A1 (en) 1998-06-30 2000-01-06 Du Pont Pharmaceuticals Company 1,3-benzodiazepin-2-ones and 1,3-benzoxazepin-2-ones useful as hiv reverse transcriptase inhibitors
GB9818731D0 (en) 1998-08-27 1998-10-21 Univ Portsmouth Compounds
CA2354774C (en) 1998-12-18 2009-05-26 Schering Corporation Farnesyl protein transferase inhibitors
CO5180550A1 (es) 1999-04-19 2002-07-30 Smithkline Beecham Corp Inhibidores de fab i
EP1227090A4 (en) 1999-10-07 2002-11-20 Tadeka Chemical Ind Ltd AMINE DERIVATIVES
US20030105118A1 (en) 2000-04-18 2003-06-05 Shuji Masumoto Tricyclic quinazolinediones
FR2812635B1 (fr) * 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
WO2002067937A1 (en) 2001-02-22 2002-09-06 School Of Pharmacy, University Of London Indoline and tetrahydro-quinolines as prodrugs for tumour treatment
FR2825705B1 (fr) * 2001-06-08 2005-05-20 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens
FR2835186B1 (fr) 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
US7439253B2 (en) * 2002-12-06 2008-10-21 Novexel Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors

Also Published As

Publication number Publication date
WO2003063864A3 (fr) 2004-03-11
CR7387A (es) 2010-10-25
TNSN04137A1 (fr) 2007-03-12
NO20043587L (no) 2004-08-27
CY2016042I1 (el) 2017-03-15
CR20120356A (es) 2012-10-05
HK1077205A1 (zh) 2006-02-10
KR20040081473A (ko) 2004-09-21
CA2474043A1 (fr) 2003-08-07
JO2646B1 (en) 2012-06-17
FR2835186B1 (fr) 2006-10-20
EA007220B1 (ru) 2006-08-25
US20090215747A1 (en) 2009-08-27
ATE484281T1 (de) 2010-10-15
LTPA2016037I1 (lt) 2017-01-10
CA2474043C (fr) 2011-08-02
DE60334527D1 (de) 2010-11-25
BRPI0307267B1 (pt) 2016-02-10
AR100790A2 (es) 2016-11-02
NL300847I2 (da) 2017-01-03
US20100048528A1 (en) 2010-02-25
OA12761A (fr) 2006-07-04
PL220725B1 (pl) 2015-12-31
EA200400981A1 (ru) 2005-02-24
EP1480644B1 (fr) 2010-10-13
HRP20040686A2 (en) 2004-12-31
NO2016024I2 (no) 2016-12-15
ES2356813T3 (es) 2011-04-13
UY27626A1 (es) 2003-08-29
CL2011000009A1 (es) 2011-03-25
KR100979079B1 (ko) 2010-08-31
UA80271C2 (uk) 2007-09-10
PT1480644E (pt) 2011-01-17
CN100482225C (zh) 2009-04-29
CN100563653C (zh) 2009-12-02
YU65804A (sh) 2006-08-17
NO335195B1 (no) 2014-10-20
LTC1480644I2 (lt) 2018-09-10
BRPI0307267B8 (pt) 2021-05-25
AR038234A1 (es) 2005-01-05
MA26351A1 (fr) 2004-10-01
MXPA04006621A (es) 2004-10-04
US20050020572A1 (en) 2005-01-27
ECSP045193A (es) 2004-08-27
JP4472346B2 (ja) 2010-06-02
NO2025027I1 (no) 2025-06-13
NZ533936A (en) 2007-05-31
NO2016024I1 (no) 2016-12-15
RS52137B (sr) 2012-08-31
CN1994301A (zh) 2007-07-11
MY140638A (en) 2010-01-15
CN101406471A (zh) 2009-04-15
IL163167A (en) 2010-04-15
PT2279737E (pt) 2013-02-01
BR0307267A (pt) 2004-12-07
BE2016C069I2 (da) 2022-05-17
FR16C1019I1 (fr) 2017-02-03
PL371601A1 (pl) 2005-06-27
CO5601014A2 (es) 2006-01-31
HRP20040686B1 (hr) 2013-02-28
AU2003214335B2 (en) 2007-04-05
HK1105864A1 (zh) 2008-02-29
FR2835186A1 (fr) 2003-08-01
HUS1600055I1 (hu) 2017-01-30
CY2016042I2 (el) 2017-03-15
US20110245254A1 (en) 2011-10-06
SI1480644T1 (sl) 2011-03-31
FR16C1019I2 (fr) 2017-12-29
EP2279737A1 (fr) 2011-02-02
SI2279737T1 (sl) 2013-07-31
EP1480644A2 (fr) 2004-12-01
PE20030969A1 (es) 2003-12-12
TW200303305A (en) 2003-09-01
JP2005523897A (ja) 2005-08-11
US7612087B2 (en) 2009-11-03
ES2401855T3 (es) 2013-04-25
EP2279737B1 (fr) 2012-10-31
CY1114417T1 (el) 2016-08-31
ZA200405607B (en) 2005-09-28
CN1655781A (zh) 2005-08-17
WO2003063864A2 (fr) 2003-08-07
TWI293071B (en) 2008-02-01
CY1111061T1 (el) 2015-06-11
DK1480644T3 (da) 2011-01-24

Similar Documents

Publication Publication Date Title
DK2279737T3 (da) Heterocycliske forbindelser, der er aktive som beta-lactamaseinhibitorer
DK1551511T5 (da) Heterocykliske aromatiske forbindelser, der er anvendelige som væksthormonsekretagoger
DK1492785T3 (da) 2-hydroxy-3-heteroarylindol-derivater som GSK3-inhibitorer
NO20053340D0 (no) Substituerte dihydropyrano-indol-3,4-dion-derivater som inhibitorer for plasmigogenaktivator-1 (CPAI-1).
DK2039685T3 (da) Heterobicycliske forbindelser som P38-inhibitorer
NO20043793L (no) Nikotinamidderivater anvendelige som PDE4 inhibitorer
DK1482932T3 (da) N3-alkylerede benzimidazolderivater som MEK-inhibitorer
DK1539742T3 (da) Indolderivater, der er nyttige som histamin H3-antagonister
NO20053775D0 (no) Diazepinoindol derivater som kinaseinhibitorer.
NO20050665L (no) Pyrrolidonderivater som MAOE inhibitoere
IS7599A (is) Heterósýklískir kínasatálmar
DK1944305T3 (da) Quinolinderivater som phosphodiesteraseinhibitorer
DE60313872D1 (de) Pyrazoloä1,5-aüpyrimidine als hemmstoffe cyclin-abhängiger kinasen
DK1699797T3 (da) Pyrrolotriazinforbindelser som kinasehæmmere
IS8483A (is) Heterósýklísk virk efni gegn mígreni
SE0701538L (sv) Azaspiroalkanderivat som hämmare av metalloproteaser
DK1499316T3 (da) (1-4-piperidinyl)benzimidazolderivater anvendelige som histamin-H3-antagonister
DK1501787T3 (da) N-biphenylmethylaminocycloalkancarboxamid-derivater med en substituerent på methyl, der er nyttige som bradykininantagonister
NO20051236L (no) Heterobiarylderivater som matriksmetalloproteinaseinhibitorer
DK1711177T3 (da) 1H-thieno-2,3-c-pyrazolderivater, der er egnede som kinase-I-inhibitorer
DK1651640T3 (da) Nicotinamid derivater, der er anvendelige som PDE4 inhibitorer
DK1954668T3 (da) Homo- og heterocykliske forbindelser, der er egnede som CETP-inhibitorer
DK1741714T3 (da) Heterocyklisk forbindelse og middel mod ondartet turmor, der indeholder denne som aktiv ingrediens
DK1828166T3 (da) Hydantoinderivater, der kan anvendes som metalloproteinase-inhibitorer
DK1390351T3 (da) Pyrimidinderivater, der er nyttige som selektive COX-2-inhibitorer